drugset / Trial / NCT07266168
Efficacy and Safety of Ivarmacitinib in the Treatment of Patients With Polymyalgia Rheumatica
Not yet recruiting
80 enrolled
Second Affiliated Hospital, School of Medicine, Zhejiang University
Affiliated Hospital of Jiaxing University · collabChangxing People's Hospital · collabFirst Affiliated Hospital of Ningbo University · collabFirst Affiliated Hospital of Wenzhou Medical University · collabFirst People's Hospital of Hangzhou · collabHuzhou Central Hospital · collabJinhua Central Hospital · collabNingbo Medical Center Lihuili Hospital · collabQilu Hospital of Shandong University · collabRenJi Hospital · collabRuijin Hospital · collabShanghai Zhongshan Hospital · collabThe First Affiliated Hospital of Nanchang University · collabThe Second Affiliated Hospital of Jiaxing University · collab
RandomizedParallel-groupDouble-blindTreatment
Summary
The study intends to explore the efficacy and safety of Ivarmacitinib in therapy for polymyalgia rheumatica through a multicenter, randomized, double-blind, placebo-controlled study, and to explore the effectiveness of Ivarmacitinib as an oral glucocorticoid-sparing alternative in the treatment of polymyalgia rheumatica.
Timeline
- Start
- 2026-01-20
- Primary completion
- 2027-12-30
- Completion
- 2028-11-30
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Comparator | SHR0302 | Unknown | 4 mg | Oral |